How research on chronic illnesses will improve COVID-19 treatment

February 10, 2021

A new paper in Oxford Open Immunology, published by Oxford University Press, examines prior findings in the field of neuroimmunology that suggest potential treatment strategies for patients suffering long-term symptoms from COVID-19.

Though COVID-19 was initially believed to be a short-term illness, lasting between one and three weeks, it's clear that a substantial number of patients will experience symptoms beyond that, with some patients suffering from health problems for more 12 weeks. In fact, for patients who were initially hospitalized, more than 80% reported at least one symptom that persisted beyond the first month.

The symptoms of long-COVID can vary widely, including cough, low grade fever, fatigue, chest pain, shortness of breath, headaches, cognitive difficulties, muscle pain and weaknesses, gastrointestinal distress, rashes, metabolic disruption, depression and other mental health conditions. In the context of other disorders and syndromes, these symptoms appear to have a strong link with a challenge to the immune system. Even mild infections and low-grade inflammation can cause depression or persistent fatigue.

As a number of causes have been proposed to explain the persistence of these long-term COVID symptoms - from the presence of persistent low viral load and reinfection, to changes in immune cell activity and tissue damage caused by the initial infection - researchers here explored insights gained in recent decades from several large-scale studies of chronic fatigue syndrome, fibromyalgia, depression and other mental health disorders that show immune abnormalities.

Researchers at King's College London here argue that several possible pathways could be relevant to understanding the persistence of long-COVID, like the involvement of glial cells and the permeability of the blood brain barrier. They also propose strategies to manage symptoms. Some of the symptoms of long-COVID, depression and other mental health problems, are related to chronic, low-grade inflammation. As such, current treatment strategies for patients with depression include anti-inflammatory medications. Psychosocial factors are also very important in regulating our immune activation. It's clear that strategies tackling a patient's level of stress with increased social support, physical exercise, and an adjusted diet could also be useful in managing long term symptoms related to COVID-19.

"We are suggesting taking advantage of what we have learnt over the years about how the brain and the immune system communicate and about the contribution of the immune system to the development of symptoms of long-COVID in other medical conditions," said the paper's lead author, Valeria Mondelli. "This is likely to accelerate our understanding of the mechanisms underlying long-COVID and the identification of effective treatments."
-end-


Oxford University Press USA

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.